PLANTATION, Fla., March 16, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service line needs, announced today its financial results for the quarter and year ended December 31, 2021.

Fourth Quarter 2021 Highlights

  • Akumin delivered strong quarterly same store volume performance on a consolidated, pro forma basis:
    • +6.2% for MRI
    • +4.2% for PET/CT
    • +3.0% for Total Radiology Procedures
    • +4.5% for Oncology Patient Starts
  • The Company reported revenue totaling $179.4 million for the fourth quarter, a $112.6 million or 168.3% increase over the fourth quarter of last year. On a sequential basis, revenue increased $71.3 million or 65.9% over the third quarter of 2021.
  • Akumin generated $27.5 million of Adjusted EBITDA (as defined below) for the quarter, a $14.0 million or 103.6% increase over the fourth quarter of last year. On a sequential basis, Adjusted EBITDA increased $9.6 million or 53.2% over the third quarter of 2021.

Summary Consolidated Financial Results (in thousands, except for per share amounts)


3-month period
ended
Dec 31, 2021

3-month period
ended
Dec 31, 2020


Year ended
Dec 31, 2021


Year ended
Dec 31, 2020

MRI Scans

217

86

539

326

PET-CT Scans

32

2

46

6

Total Scans

545

339

1,683

1,242

Oncology Patient Starts

2

-

3

-

Revenue

$179,443

$66,879

$421,079

$245,626

Adjusted EBITDA (1)

$27,522

$13,519

$66,903

$42,078

EPS –Diluted

$(0.36)

$(0.27)

$(0.56)

$(0.52)

(1) See "Non-GAAP Measures" below.

Commenting on the year-end results, Riadh Zine, Chairman and Co-Chief Executive Officer of the Company, said, "Q4 2021 marked the first full quarter of combined results following Akumin's acquisition of Alliance HealthCare Services on September 1, 2021.  We are pleased that we were able to deliver financial results, well within our guidance range in the quarter, notwithstanding the disruptions caused by Omicron and the impact of an additional collection reserve related to the attorney business because of court backlogs following a 15-month shutdown. 

"Although Omicron continued to disrupt the business in the early part of 2022, we are pleased that we have seen a strong rebound to normalized levels which speaks to the resilience of Akumin's business.  As an essential healthcare service provider, we continue to serve our valued patients and partners and we remain optimistic that we will recover the pandemic-related volume lag in the subsequent quarters, barring any unforeseen variants," Mr. Zine continued.

"Akumin's vision is to drive patient-centered innovation, service delivery standardization, and exceptional healthcare value, all in an outpatient care setting to hospital and health system relationships.  Our integration and transformative initiatives are underway, and we continue to expect 2022 to be a milestone year as we build on this solid foundation" Mr. Zine concluded.

Unless otherwise indicated, all amounts are expressed in U.S. dollars.  Certain metrics, including those expressed on an adjusted or comparable basis, are non-GAAP measures.  See "Non-GAAP Measures" and "Selected Consolidated Financial Information" of this press release for further details. 

As previously announced, effective January 1, 2022, the Company ceased to qualify as a foreign private issuer in the United States.  As a result, from and after January 1, 2022, in addition to other obligations, Akumin now files its annual consolidated financial statements and management's discussions and analysis on the Securities and Exchange Commission Form 10-K, the U.S. domestic issuer form.  Copies of these filings are available in Akumin's public disclosure at www.sec.gov and www.sedar.com.

Investor Presentation

Akumin would like to invite interested parties to an investor presentation to be held on Thursday, March 17, 2022 from 8:00 a.m. to 9:00 a.m. Eastern Time where management will discuss fourth quarter and yearend results.

Conference call details:

Date:

8:00a.m. Eastern Time, Thursday, March 17, 2022

Toll-free:

888-256-1007

International Callers:

647-484-0478.

A related presentation will be available from Akumin's website (www.akumin.com) and at https://akum.in/2021-ResultsCall. Participants are asked to connect at least 10 minutes prior to the beginning of the call to ensure participation.  The webcast archive will be available for 90 days.  A replay of the presentation will also be available by calling 1-888-203-1112, or 647-436-0148 for international callers, using passcode 4560419.

About Akumin

Akumin is a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service line needs. Akumin provides: (1) fixed-site outpatient diagnostic imaging services through a network of more than 200 owned and/or operated imaging locations; and (2) outpatient radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. By combining clinical and operational expertise with the latest advances in technology and information systems, Akumin facilitates more efficient and effective diagnosis and treatment for patients and their providers.  Akumin's imaging procedures include MRI, CT, positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and other interventional procedures; cancer care services include a full suite of radiation therapy and related offerings. For more information, visit www.akumin.com and www.alliancehealthcareservices-us.com.

Non-GAAP Measures

This press release refers to certain non-GAAP measures. These non-GAAP measures are not recognized measures under United States generally accepted accounting principles ("GAAP") and do not have a standardized meaning prescribed by GAAP.  There is unlikely to be comparable or similar measures presented by other companies. Rather, these non-GAAP measures are provided as additional information to complement those GAAP measures by providing further understanding of our results of operations from management's perspective. Accordingly, these non-GAAP measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under GAAP. We use non-GAAP financial measures, including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA Margin" (each as defined below). These non-GAAP measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on GAAP measures. We believe the use of these non-GAAP measures, along with GAAP financial measures, enhances the reader's understanding of our operating results and is useful to us and to investors in comparing performance with competitors, estimating enterprise value, and making investment decisions.  We also believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management uses non-GAAP measures to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Definitions and reconciliations of non-GAAP measures to the relevant reported measures can be found in our Form 10-K filed March 16, 2022 available in our public disclosure at www.sec.gov and www.sedar.com.

We define such non-GAAP measures as follows:

"EBITDA" means net income (loss) before interest expense (net), income tax expense (benefit), and depreciation and amortization.

"Adjusted EBITDA" means EBITDA, as further adjusted for stock-based compensation, asset impairments, settlement and related costs (recoveries), financial instrument revaluation and related losses (gains), loss on extinguishment of debt, acquisition-related costs, severance and related costs, restructuring charges, other losses (gains), deferred rent expense (credit), and one-time adjustments.

"Adjusted EBITDA Margin" means Adjusted EBITDA divided by the total revenue in the period.

Forward-Looking Information

Certain information in this press release constitutes forward-looking information or forward-looking statements.  In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.  Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of our Form 10-K filed March 16, 2022, which is available at www.sec.gov and www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully.  There can be no assurance that such estimates and assumptions will prove to be correct.  The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Selected Consolidated Financial Information

(in thousands)

Three-month
period
ended
Dec 31, 2021

Three-month
period
ended
Dec 31, 2020

 

 

$ Change

 

 

% Change

Service fees – net of allowances and
discounts

177,202

62,283

114,919

185%

Other revenue

2,241

4,596

(2,355)

(51%)

Revenue

179,443

66,879

112,564

168%






Employee compensation

75,365

21,966

53,399

243%

Reading fees

11,200

9,964

1,236

12%

Rent and utilities

12,305

7,319

4,986

68%

Third party services and professional
fees

31,233

7,269

23,964

330%

Administrative

10,616

3,351

7,265

217%

Medical supplies and other expenses

14,610

3,178

11,432

360%

Depreciation and amortization

24,536

4,059

20,477

504%

Stock-based compensation

795

358

437

122%

Other operating losses

305

352

(47)

(13%)

Interest expense

28,354

8,344

20,010

240%

Settlement and related recoveries

(145)

(167)

22

(13%)

Acquisition related costs

5,821

605

5,216

nmf

Other non-operating losses (gains)

(528)

18,198

(18,726)

(103%)

Loss before income taxes

(35,024)

(17,917)

(17,107)

95%

Income tax expense (benefit)

(8,392)

64

(8,456)

nmf

Non-controlling interest

5,089

709

4,380

618%

Net loss attributable to common
shareholders

(31,721)

(18,690)

(13,031)

70%

 

(in thousands)

Year
Ended
Dec 31, 2021

Year
Ended
Dec 31, 2020

$ Change

% Change

Service fees – net of allowances and
discounts

416,074

238,324

177,750

75%

Other revenue

5,005

7,302

(2,297)

(31%)

Revenue

421,079

245,626

175,453

71%






Employee compensation

164,053

84,038

80,015

95%

Reading fees

42,842

37,818

5,024

13%

Rent and utilities

37,158

30,203

6,955

23%

Third party services and professional
fees

63,301

30,183

33,118

110%

Administrative

24,660

12,231

12,429

102%

Medical supplies and other expenses

27,721

11,162

16,559

148%

Depreciation and amortization

44,895

17,060

27,835

163%

Stock-based compensation

2,792

2,084

708

34%

Other operating losses (gains)

583

(4,130)

4,713

(114%)

Interest expense

62,575

32,781

29,794

91%

Settlement and related costs
(recoveries)

(539)

2,324

(2,863)

(123%)

Acquisition related costs

20,233

1,079

19,154

nmf

Other non-operating losses (gains)

(3,990)

22,387

(26,377)

(118%)

Loss before income taxes

(65,205)

(33,594)

(31,611)

94%

Income tax expense (benefit)

(30,391)

562

(30,953)

nmf

Non-controlling interest

8,477

2,585

5,892

228%

Net loss attributable to common
shareholders

(43,291)

(36,741)

(6,550)

(18%)

 

(in thousands)

Three-month
period
ended
Dec 31, 2021

Three-month
period
ended
Dec 31, 2020

Year
ended
Dec 31, 2021

Year
ended
Dec 31, 2020

Net loss

(26,632)

(17,981)

(34,814)

(34,156)

Income tax expense (benefit)

(8,392)

64

(30,391)

562

Depreciation and amortization

24,536

4,059

44,895

17,060

Interest expense

28,354

8,344

62,575

32,781

EBITDA

17,866

(5,514)

42,265

16,247

Adjustments:





Stock-based compensation

795

358

2,792

2,084

Settlement and related costs
(recoveries)

(145)

(167)

(539)

2,324

Acquisition-related costs

5,821

605

20,233

1,079

Gain on revaluation of earn-out
liability

-

-

-

(5,457)

Loss on extinguishment of debt

-

18,279

-

18,279

Loss (gain) on settlement of
interest rate cap derivative

-

(101)

-

4,162

Gain on conversion of debt to
equity investment

-

-

(3,360)

-

Other losses, net

72

108

342

407

Severance, restructuring and other
charges

2,836

-

3,368

-

Deferred rent expense(1)

277

(49)

1,802

2,953

Adjusted EBITDA

27,522

13,519

66,903

42,078

Revenue

179,443

66,879

421,079

245,626

Adjusted EBITDA Margin

15%

20%

16%

17%


(1)  Deferred rent expense is defined as operating lease cost less operating cash flows from operating leases and adjusted for any prepayments or related items.

 

Cision View original content:https://www.prnewswire.com/news-releases/akumin-announces-fourth-quarter-2021-results-301504494.html

SOURCE Akumin Inc.

Copyright 2022 PR Newswire

Akumin (TSX:AKU)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Akumin Charts.
Akumin (TSX:AKU)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Akumin Charts.